NMR lipoprotein profile: particle subfractions and GlycA in RA-BEAM
| Placebo n=488 | Baricitinib 4 mg n=487 | Adalimumab n=330 | |
| Mean number of particles (nmol/L) | |||
| Total LDL | |||
| Baseline | 1178.60 (398.50) | 1178.16 (335.46) | 1165.15 (330.16) |
| Change from baseline at week 12 | −21.31 (12.25) | 15.77 (12.09)*++ | −36.64 (14.77) |
| Large LDL | |||
| Baseline | 513.31 (216.87) | 506.54 (225.29) | 501.96 (227.72) |
| Change from baseline at week 12 | −0.72 (8.20) | 81.74 (8.09)***+++ | 39.49 (9.89)** |
| Small LDL | |||
| Baseline | 632.45 (415.25) | 637.68 (374.39) | 633.34 (372.48) |
| Change from baseline at week 12 | −21.86 (15.09) | −80.26 (14.89)** | −82.86 (18.18)** |
| Medium small LDL | |||
| Baseline | 127.25 (83.21) | 130.05 (77.97) | 128.35 (77.36) |
| Change from baseline at week 12 | −3.18 (3.15) | −16.29 (3.11)** | −15.47 (3.80)* |
| Very small LDL | |||
| Baseline | 505.26 (333.70) | 507.64 (298.81) | 504.94 (297.13) |
| Change from baseline at week 12 | −18.76 (12.07) | −63.93 (11.91)** | −67.37 (14.55)* |
| Total HDL | |||
| Baseline | 28.88 (5.90) | 28.69 (5.96) | 28.48 (5.84) |
| Change from baseline at week 12 | 0.06 (0.22) | 4.73 (0.21)***+++ | 1.93 (0.26)*** |
| Large HDL | |||
| Baseline | 9.01 (3.41) | 9.13 (3.48) | 8.91 (3.56) |
| Change from baseline at week 12 | 0.00 (0.12) | 0.98 (0.12)***++ | 0.41 (0.14)* |
| Medium HDL | |||
| Baseline | 2.82 (3.27) | 2.68 (3.01) | 2.89 (3.27) |
| Change from baseline at week 12 | 0.13 (0.14) | 0.63 (0.14)*+++ | −0.30 (0.17)* |
| Small HDL (nmol/L) | |||
| Baseline | 17.04 (5.59) | 16.88 (5.66) | 16.68 (5.54) |
| Change from baseline at week 12 | −0.08 (0.21) | 3.08 (0.21)***+++ | 1.86 (0.25)*** |
| Mean particle size (nm) | |||
| LDL particle size | |||
| Baseline | 21.34 (0.76) | 21.29 (0.75) | 21.28 (0.74) |
| Change from baseline at week 12 | 0.02 (0.03) | 0.25 (0.03)*** | 0.23 (0.03)*** |
| VLDL particle size | |||
| Baseline | 47.59 (9.29) | 46.94 (9.09) | 47.90 (11.61) |
| Change from baseline at week 12 | 0.57 (0.40) | 2.34 (0.40)** | 1.19 (0.49) |
| HDL particle size | |||
| Baseline | 9.34 (0.47) | 9.33 (0.46) | 9.36 (0.49) |
| Change from baseline at week 12 | 0.01 (0.01) | −0.02 (0.01)* | −0.00 (0.01) |
| Mean levels of GlycA (µmol/L) | |||
| Baseline | 508.9 (104.6) | 517.2 (114.4) | 513.9 (106.4) |
| Change from baseline at week 12 | −13.6 (3.8) | −110.9 (3.8)***+ | −98.7 (4.7)*** |
Baseline data are mean (SD); change from baseline data are least squares mean (SE).
*P≤0.05; **P≤0.01; ***P≤0.001 versus placebo. +P≤0.05; ++P≤0.01; +++P≤0.001 versus adalimumab.
HDL, high-density lipoprotein; LDL, low-density lipoprotein; NMR, nuclear magnetic resonance; RA, rheumatoid arthritis; VLDL, very-low-density lipoprotein.